DE3007226A1 - Soft gelatin capsules with wound-healing effect for local application - contg. aq/ soln. of chlorhexidine and allantoin thickened with polyethylene glycol(s) - Google Patents

Soft gelatin capsules with wound-healing effect for local application - contg. aq/ soln. of chlorhexidine and allantoin thickened with polyethylene glycol(s)

Info

Publication number
DE3007226A1
DE3007226A1 DE19803007226 DE3007226A DE3007226A1 DE 3007226 A1 DE3007226 A1 DE 3007226A1 DE 19803007226 DE19803007226 DE 19803007226 DE 3007226 A DE3007226 A DE 3007226A DE 3007226 A1 DE3007226 A1 DE 3007226A1
Authority
DE
Germany
Prior art keywords
chlorhexidine
allantoin
capsules
soft gelatin
thickened
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19803007226
Other languages
German (de)
Inventor
Erich 2400 Lübeck Hofacker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE19803007226 priority Critical patent/DE3007226A1/en
Publication of DE3007226A1 publication Critical patent/DE3007226A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Abstract

New soft gelatin medicinal capsules contain an aq soln, thickened with polyethylene glycols, of a mixture of chlorhexidine and allantoin, as well as polyols, and the capsule wall consists of phargelatin,ceutical, ma softeners and opt, preservatives, pigments and/or dyes. Chlorhexidine and allantoin exert a synergistic effect on healing processes. The new capsules are intended for insertion in body cavities, where the active components are gradually released to exert a local wound-healing effect. The capsules have practically unlimited shelf life under normal storage conditions, but local tolerance is good and good solubility and prolonged action properties are retained.

Description

r zne ikap sel r zne ikap sel

Chlorhexidin (1,1'-Hexamethylen-bis (5-Chlorphenyl)-biguanid) ist als wirksames Chemotherapeutikum bekannt. Es hat einen weiten Anwendungsbereich im Mund- und Rachenraum als Desinfiziens und Prophylaktikum zur Behandlung entzündlicher und infektiöser Erkrankungen sowie zur Mundhygiene.Is chlorhexidine (1,1'-hexamethylene bis (5-chlorophenyl) biguanide) known as an effective chemotherapeutic agent. It has a wide range of uses in the mouth and throat as a disinfectant and prophylactic for the treatment of inflammatory and infectious diseases as well as oral hygiene.

Eine Verabreichung von Chlorhexidin zusammen mit Allantoin (5-Ureido-hydantoin), das zur Behandlung von Wunden bekannt ist, hat einen überraschend großen Effekt auf den Heilungsprozeß entsundlicher Veränderungen im Sinne einer synergistischen Wirkung.Administration of chlorhexidine together with allantoin (5-ureido-hydantoin), which is known for the treatment of wounds, has a surprisingly great effect on the healing process of substantial changes in the sense of a synergistic one Effect.

Eine längere Zeit anhaltende lokale Wirkung, wie sie insbesondere bei Darm- oder Scheidenentzündungen und dergleichen erwunscht ist, setzt allerdings voraus, daß die Wirkstoffe in einer Applikationsform in die Eörperöffnung eingeführt werden, die eine allmähliche yreisetzung bei gleichzeitiger optimaler Verträglichkeit der mitrezeptierten Hilfsstoffe ermöglicht.A long-lasting local effect, such as that in particular with intestinal or vaginal inflammation and the like is desired, however, sets requires that the active ingredients are introduced into the orifice of the body in an application form that a gradual release with optimal tolerance at the same time the co-formulated excipients.

Dazu ist eine Weichgelatine-Eapsel, die sich in den wässrigen Korperflüssigkeiten und Sekreten löst, hervorragend geeignet.In addition there is a soft gelatin capsule, which is immersed in the aqueous body fluids and dissolves secretions, excellently suited.

Die Anwendung von Chlorhexidin und Allantoin für den vorgesehenen Verwendungszweck ist in stark verdünnter wässriger Lösung therapeutisch optimal. Es gelingt jedoch nicht, eine wässrige Lösung der Wirkstoffe ohne weiteres in einer Weichgelatine-Eapsel unterzubringen, da die Kapseln durch ihren eigenen wässrigen Inhalt aufgelöst würden.The application of chlorhexidine and allantoin for the intended Intended use is therapeutically optimal in a highly diluted aqueous solution. However, it is not possible to easily convert an aqueous solution of the active ingredients into one Soft gelatin capsules accommodate the capsules by their own watery Content would be resolved.

Die Aufgabe der Erfindung besteht somit darin, eine Zusammensetzung sowohl für den Kapselinhalt als auch für die Eapselhülle zu finden, die zwar eine gute Auflösung der Kapseln in den menschlichen Sorperflüssigkeiten ermöglicht, aber andererseits eine genügende Haltbarkeit der gefüllten Kapseln bei normalen Aufbewahrngsbedingungen sicherstellt.The object of the invention is thus to provide a composition to be found for both the capsule content and the capsule shell, although one allows good dissolution of the capsules in the human sorptive fluids, but on the other hand, a sufficient shelf life of the filled capsules under normal storage conditions ensures.

Diese Aufgabe wird nun erfindungsgemäß dadurch gelöst, daß die in die Kapsel einzuschließende Lösung aus Chlorhexidin und Allantoin mit einem Vberschuß an Polyäthylenglykolen, vorzugsweise höheren Molekulargewichtes, versetzt wird, wobei Polyole, vorzugsweise Glycerin, die Geschmeidigkeit und Verträglichkeit des Kapselinhaltes verbessern. Die Kapselhülle besteht aus Gelatine pharmazeutischer Qualität und geeigneten Weichmachern, vorzugsweise Glycerin, und färbenden und/oder opakmachenden Substanzen wie etwa Titandioxid oder Eisenoxiden. Weiterhin können Eonservierungsmittel vorhanden sein.This object is now achieved according to the invention in that the in the solution of chlorhexidine and allantoin to be enclosed in the capsule with an excess polyethylene glycols, preferably of higher molecular weight, are added, polyols, preferably glycerine, the suppleness and compatibility of the Improve the capsule content. The capsule shell is made of pharmaceutical gelatin Quality and suitable plasticizers, preferably glycerin, and coloring and / or opacifying substances such as titanium dioxide or iron oxides. Furthermore you can Preservatives should be available.

Derart hergestellte Kapseln weisen überraschenderweise eine praktisch unbegrenzte Haltbarkeit unter normalen Lagerbedingungen, andererseits jedoch eine gute Löslichkeit und Langzeitwirknng in Korperhöhlen bei ausgezeichn~eter Verträglichkeit auf, wenn sie in der Scheide, im Darm oder dergleichen appliziert werden.Capsules produced in this way surprisingly have a practical unlimited shelf life under normal storage conditions, but on the other hand one good solubility and long-term effect in body cavities with excellent tolerance when they are applied in the vagina, intestine or the like.

Eine bevorzugte Rezeptur für eine solche Kapsel ist die folgende: Zusammensetzung mg pro Kapsel Polyäthylenglykol 400 1.187,0 Polyäthylenglykol 4000 125,0 Chlorhexidin-digluconat 20 %ig 30,0 Allantoin 8,0 Glycerin 50,0 Kapselhülle Gelatine 60 - 70 % Glycerin 30 - 40 % p-Hydroxybenzoesäure-äthylester-Na-salz 0,3 % p-Hydroxybenzoesäure-propylester-Na-salz 0,15 % Titandioxid 1,0 % Eisenoxidgelb 0,1 % Die Wirkung der neuen Kapsel wird durch folgende Versuche belegt: Bei 31 Patientinnen mit einer starken Scheidenentzündung wurde eine Behandlung mit den oben beschriebenen Kapseln durchgeführt. Die Behandlung erfolgte an 10 aufeinanderfolgenden Tagen mit den Kapseln und an 5 aufeinanderfolgenden Tagen mit einem östrogenhaltigen xokaltherapeutikum. Die Kapseln sollten pathogene Keime im Sinne einer ßakterizidie oder Bakteriostase beeinflussen.A preferred formulation for such a capsule is the following: Composition mg per capsule polyethylene glycol 400 1,187.0 polyethylene glycol 4000 125.0 Chlorhexidine digluconate 20% 30.0 Allantoin 8.0 Glycerin 50.0 Capsule shell Gelatine 60 - 70% glycerine 30 - 40% p-hydroxybenzoic acid ethyl ester Na salt 0.3 % p-Hydroxybenzoic acid propyl ester Na salt 0.15% titanium dioxide 1.0% iron oxide yellow 0.1% The effectiveness of the new capsule is proven by the following tests: In 31 patients with severe vaginal inflammation, treatment with those described above was given Capsules carried out. The treatment was carried out on 10 consecutive Days with the capsules and for 5 consecutive days with an estrogen-containing one xocal therapeutic agent. The capsules should contain pathogenic germs in the sense of bactericidal action or affect bacteriostasis.

Bei jener Patientin wurde vor Behandlungsbeginn ein Aus-strich-Präparat angefertigt; bei der Färbung konnten stark entzündliche Zellveränderungen sowie Staphylococcen und Streptococcen, Colibakterien, Sarcinen, Enterococcen, Bakterium proteus, aber auch Itykosen festgestellt werden.A smear preparation was given to that patient before the start of treatment prepared; the staining could cause severe inflammatory cell changes as well Staphylococci and streptococci, coli bacteria, sarcines, enterococci, bacterium proteus, but also itycoses can be detected.

Sach erfolgter Behandlung nach obigem Schema wurde überraschenderweise gefunden, daß in einer einmaligen Sur eine völlige klinische Heilung mit dem Ergebnis des Reinheitsgrades I erzielt wurde. Nur 2 Patientinnen mit Mykosen mußten noch entsprechend nachbehandelt werden.Treatment according to the above scheme has been carried out surprisingly found that in a single sur a complete clinical cure with the result of purity grade I was achieved. Only 2 patients with mycoses had to go be treated accordingly.

Die potenzierende Wirkung des Chlorhexidin-Allantoin-Gemisches in Kapselform ist also klinisch evident.The potentiating effect of the chlorhexidine-allantoin mixture in The capsule shape is therefore clinically evident.

Claims (2)

Patentansprüche 1. Weichgelatine-Arzneikapsel mit einem Gehalt an gelösten Arzneistoffen, dadurch gekennzeichnet, daß sie eine mit Polgäthylenglykolen verdickte wässrige Lösung eines Gemisches von Chlorhexidin und Allantoin sowie Polyolen enthält, während die Sapselhülle aus pharmazeutischer Gelatine, Weichmachern und gegebenenfalls EDnservierungsmitteln und Pigmenten sowie Farbstoffen besteht. Claims 1. Soft gelatin medicinal capsule with a content of dissolved medicinal substances, characterized in that they contain one with poly ethylene glycols thickened aqueous solution of a mixture of chlorhexidine and allantoin and polyols contains, while the sapsel shell is made from pharmaceutical gelatin, plasticizers and if necessary there are preservatives and pigments as well as dyes. 2. Kapsel nach Anspruch 1, dadurch gekennzeichnet, daß das Molekalargewicht der Polyäthylenglykole zwischen 200 und 10.000, vorzugsweise zwischen 400 und 4000, liegt.2. Capsule according to claim 1, characterized in that the molecular weight of the polyethylene glycols between 200 and 10,000, preferably between 400 and 4000, lies.
DE19803007226 1980-02-27 1980-02-27 Soft gelatin capsules with wound-healing effect for local application - contg. aq/ soln. of chlorhexidine and allantoin thickened with polyethylene glycol(s) Withdrawn DE3007226A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19803007226 DE3007226A1 (en) 1980-02-27 1980-02-27 Soft gelatin capsules with wound-healing effect for local application - contg. aq/ soln. of chlorhexidine and allantoin thickened with polyethylene glycol(s)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19803007226 DE3007226A1 (en) 1980-02-27 1980-02-27 Soft gelatin capsules with wound-healing effect for local application - contg. aq/ soln. of chlorhexidine and allantoin thickened with polyethylene glycol(s)

Publications (1)

Publication Number Publication Date
DE3007226A1 true DE3007226A1 (en) 1981-09-10

Family

ID=6095599

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19803007226 Withdrawn DE3007226A1 (en) 1980-02-27 1980-02-27 Soft gelatin capsules with wound-healing effect for local application - contg. aq/ soln. of chlorhexidine and allantoin thickened with polyethylene glycol(s)

Country Status (1)

Country Link
DE (1) DE3007226A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011965B2 (en) * 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
US7374754B2 (en) 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation
US8460654B2 (en) 2005-12-28 2013-06-11 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals
US8603464B2 (en) 2002-12-12 2013-12-10 Zoltan Laboratories Llc Alkaline phosphatase to reduce weight gain or induce weight loss

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7011965B2 (en) * 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
US8603464B2 (en) 2002-12-12 2013-12-10 Zoltan Laboratories Llc Alkaline phosphatase to reduce weight gain or induce weight loss
US7374754B2 (en) 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation
US8460654B2 (en) 2005-12-28 2013-06-11 Zoltan Laboratories Llc Use of alkaline phosphatase to maintain healthy tissue mass in mammals

Similar Documents

Publication Publication Date Title
EP1244434B1 (en) Use of chemotherapeutic agents
EP0773022B3 (en) Pharmaceutical composition for the treatment of rhinitus, containing sympathomometic and pantothenol and/or pantothenic acid
WO1987004350A1 (en) Process for improving the adherence of gels to mucous membranes
DE2611725A1 (en) ZINC SULPHADIAZINE AND DERMATOTHERAPEUTIC AGENTS, CONTAINING IT, FOR THE TREATMENT OF BURNS
DE3007226A1 (en) Soft gelatin capsules with wound-healing effect for local application - contg. aq/ soln. of chlorhexidine and allantoin thickened with polyethylene glycol(s)
DE19541919A1 (en) Compositions containing a pantothenol derivative and a sympathomimeticum
US20040265344A1 (en) Aloe suppositories
CH662510A5 (en) GLYCYRRHIZINE AND A MEDICINAL PRODUCT CONTAINING AN ACTIVE SUBSTANCE.
DE3736866A1 (en) MEANS FOR THE TREATMENT OF HYPERTENSION AND HEART FAILURE
DE1806926A1 (en) Lithium salt of hydroquinone sulfonic acid
EP0845264A1 (en) Partial or full extract of non fermentated Camellia sinensis L.
DE3432411A1 (en) ANTIADHAESIVE PROHYLACTICA AND MEDICINAL PRODUCTS CONTAINING A SECRETOLYTICALLY EFFECTIVE BENZYLAMINE DERIVATIVE
DE2538843A1 (en) WATER-SOLUBLE PHARMACEUTICAL COMPLEX, PROCESS FOR ITS MANUFACTURING AND PHARMACEUTICAL PREPARATIONS WHICH CONTAIN IT
DE2342214C3 (en) Remedies
RU2754828C1 (en) Dental gel for treatment of inflammatory diseases of periodontal and mucosa of oral cavity, arising on background of psychoemotional stress
DE2235348A1 (en) MEDICINAL PRODUCTS FOR TREATMENT AND USE OF GONORRHOUS
RU2013087C1 (en) Salve for treatment of a patient with highmoritis, acute or atrophic rhinitis
DE202007003896U1 (en) Pharmaceutical composition for the treatment of incontinence
DE862044C (en) Process for the production of dry preparations for the preparation of ointment bases or ointments
DE2126204A1 (en) Lysozyme preparations
DE2015877A1 (en) drug
DE1950403A1 (en) New pharmaceutical compositions based on formocaseins
DE4037658C2 (en) USE OF DERIVATIVES OF 2 ', 4', 6'-TRIMETHOXY-4- (1-PYRROLIDINYL) BUTYROPHENONE
DE743091C (en) Plastic seals, infusion compounds and medical stiffeners and processes for their manufacture
DE1617798A1 (en) Medicines and processes for their manufacture

Legal Events

Date Code Title Description
8139 Disposal/non-payment of the annual fee